A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40°C or 60% at 25°C for a period of atleast three months doesn"t change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I).